
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Give us your opinion on our latest poll, and see what your colleagues are saying. You can see the results of our previous surveys here as well.






